Hashimoto's Thyroiditis (Chronic Autoimmune Thyroiditis)
The opposite condition of Graves' disease is Hashimoto's thyroiditis—both are autoimmune thyroid disorders, but Graves' causes hyperthyroidism through TSH receptor stimulation, while Hashimoto's causes hypothyroidism through thyroid gland destruction and TSH receptor blockade. 1
Key Pathophysiologic Differences
Graves' Disease
- Mechanism: TSH receptor antibodies (TRAb) stimulate the thyroid gland, causing hyperplasia and excessive thyroid hormone production
- Result: Hyperthyroidism with elevated T4/T3 and suppressed TSH
- Clinical presentation: Weight loss, tachycardia, heat intolerance, anxiety, possible ophthalmopathy
Hashimoto's Thyroiditis
- Mechanism: TSH stimulation-blocking antibodies (TSBAb) block TSH action, leading to lymphocytic infiltration, thyroid damage, and glandular atrophy 2
- Result: Hypothyroidism with low T4/T3 and elevated TSH
- Clinical presentation: Weight gain, fatigue, cold intolerance, bradycardia, possible goiter
Important Clinical Overlap
A critical pitfall: These conditions can transition into one another or coexist. Approximately 15-20% of patients with Graves' disease develop spontaneous hypothyroidism from subsequent Hashimoto's thyroiditis 2. This transition can occur anywhere from months to 25 years after initial Graves' disease treatment 2.
Hashitoxicosis
A specific overlap syndrome exists called "hashitoxicosis"—a transient hyperthyroid phase occurring in Hashimoto's disease 1:
- Occurs in 5% of children with thyroiditis
- Hyperthyroid phase lasts 1-6 months (shorter than Graves' disease)
- Usually lacks TSH receptor antibodies but has anti-TPO antibodies present
- Less than 5% of cases transition between thyroiditis and Graves' disease in either direction 1
Diagnostic Distinctions
Antibody patterns differ markedly 3:
- Graves': Positive TRAb (stimulating antibodies), may have anti-TPO
- Hashimoto's: Positive anti-TPO and anti-thyroglobulin antibodies, typically negative TRAb
- Serum soluble CD8 levels change in opposite directions during active disease phases 3
Monitoring After Graves' Treatment
Critical follow-up requirement: Even after successful Graves' disease treatment, monitor thyroid function yearly or every 2 years, as 5-20% of patients spontaneously progress to hypothyroidism without radioiodine or surgery 4. This represents evolution toward Hashimoto's pathophysiology in the same autoimmune spectrum.